The Quantellect read.As of Nov 19, 2026, 3 active firms cover Envoy Medical Inc: 3 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $2.00 to $2.50, so the covering firms are broadly aligned. The average target of $2.17 sits 69% below the current $6.91. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 2 to 3 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.61 next quarter toward $-2.44 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 active firms
Buy
Strong Buy00%
Buy3100%
Neutral00%
Sell00%
Strong Sell00%
Based on 3 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$2.17
-68.6% downside
Average target across 3 active firms as of Nov 19, 2026 vs $6.91 current
Highest Target$2.50
Average Target$2.17
Lowest Target$2.00
Detailed analyst forecasts for COCH
Showing 1–3 of 3 named analysts shown · 3 active firms in the rating projection
As of Nov 19, 2026, 3 of 3 active firms rate COCH a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
COCH EPS & revenue forecast
EPS · NEXT QUARTER
$-0.61
Range $-0.66 – $-0.53 · 3 analysts · -24% YoY
Next period, 3 analysts expect Envoy Medical Inc. to earn $-0.61 a share (range $-0.66 – $-0.53), versus $-0.80 a year earlier. Full-year consensus is $-2.62, growing to $-2.44 the year after.
REVENUE · NEXT QUARTER
$100.0K
Range $100.0K – $100.0K · 3 analysts · +156% YoY
Revenue is expected to reach $100.0K (range $100.0K – $100.0K), +156.4% year-over-year. Full-year consensus is $237.0K, rising to $273.3K next year.
Top analysts covering Envoy Medical Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on COCH.
#1
Yi Chen
HC Wainwright & Co. · Rank #350
Buy
$2.00-71.0% to target
Overall win rate
34%
+ Follow
#2
Frank Takkinen
Lake Street · Rank #514
Buy
$2.50-63.8% to target
Overall win rate
27%
+ Follow
#3
Edward Woo
Ascendiant Capital · Rank #570
Buy
$9.50+37.6% to target
Overall win rate
24%
+ Follow
#4
Carl Byrnes
Northland Capital Markets
Buy
$5.00-27.6% to target
Coverage
—
+ Follow
#5
EW
Edward Woo
Ascendiant
Buy
$9.50+37.6% to target
Coverage
—
+ Follow
COCH stock forecast FAQ
What is COCH's average 12-month price target?+
The 3 active firms with a live target average $2.17 for Envoy Medical Inc. over the next 12 months, ranging from a $2.50 high to a $2.00 low, as of Nov 19, 2026.
Is COCH stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 3 active firms as of Nov 19, 2026, 3 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for COCH?+
The Street-high target is $2.50 (Lake Street), and the Street-low is $2.00 (HC Wainwright & Co.). The average of all 3 active-firm targets is $2.17.
How many active Wall Street firms cover COCH?+
3 active firms have a recognized rating on Envoy Medical Inc. as of Nov 19, 2026, and 3 active firms carry a live 12-month price target.
Who is the most accurate analyst covering COCH?+
Among analysts who currently cover COCH, Yi Chen of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #350). Their current call is Buy with a $2.00 target.
What is Envoy Medical Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.61 per share (range $-0.66 – $-0.53) across 3 analysts. Full-year EPS is projected at $-2.62, rising to $-2.44 the following year.
How much revenue is Envoy Medical Inc. expected to report next quarter?+
Consensus revenue is $100.0K (range $100.0K – $100.0K). Full-year revenue is projected at $237.0K, growing to $273.3K next year.
Have analysts been upgrading or downgrading COCH lately?+
As of Nov 19, 2026, 3 of 3 active firms rate COCH a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their COCH calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.